A clinical study to compare the results of Kuberaksha Vati and Dashmoola Taila Matra Basti in patients having pain during menstruation

A comparative clinical study to evaluate the efficacy of Kuberaksha vati and Dashmoola Taila Matra Basti in the management of Udavartini yonivyapad with special reference to primary dysmenorrhea. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/06/089734

Enrollment

Registered

2025-06-27

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N944- Primary dysmenorrhea

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.female patient of age 16 to 35 years. 2.Patient suffering from pain during mensuration for more than 3 consecutive cycle. 3.Patient coming with chief complaint of pain during menses with or without associated symptoms. 4. Patient willing and able to participate in study.

Exclusion criteria

Exclusion criteria: 1.Female patients age below 16 years and above 35 years of age. 2.Patients with any identifiable pelvic pathology like fibroids, adenomyosis, endometriosis, PID, UTI etc. 3.Patients using IUD /oral contraceptive pills. 4.Patient have H/O hypothyroidism and hyperthyroidism with DUB . 5.Patients with systemic disorders like Tuberculosis, Hypertension, Diabetes mellitus, anemia etc. 6.Patient not willing for trial.

Design outcomes

Primary

Measure	Time frame
1.To evaluate the efficacy of Kuberaksha vati and Dashmoola taila matra basti in the management of udavartini yonivyapad. 2.To compare the efficacy of Kuberaksha vati and Kuberaksha vati with Dashmoola Taila Matra Basti.Timepoint: 1.after 4 weeks 2.after 4 weeks	—

Secondary

Measure	Time frame
1.Conceptual Study of Udavartini Yonivyapada. 2.To find out safe & potent drug for Udavartini Yonivyapada. 3.Decrease in pain during menses. 4.reduction in associated menstrual problems. 5.To evaluate any adverse effects associated with treatment.Timepoint: 1.after 4 weeks 2.after 4 weeks	—

Countries

India

Contacts

Public ContactDr Shubhi Mishra

State Ayurvedic College and Hospital, Tulsidas marg, Turiyaganj, Lucknow

drshikhasharma1982@gmail.com8743976379

Outcome results